Videos

Following FDA approval, GigaGen's therapy enters Phase 1 clinical trials as the first recombinant human polyclonal therapy for hepatitis B.

Part 1, Deborah Birx, MD explains photohydrolysis technology provides continuous, automated disinfection of air and surfaces effective in controlling MRSA and improving infection control practices in healthcare settings.

Kate Broderick, PhD, molecular geneticist, discusses the mRNA capping technology and how it helps create stability to mRNA molecules within vaccines and guides them to cells.

In the second episode with Michael Laposata, MD, PhD, he discusses how lab professionals can communicate with infectious disease clinicians, how AI can be used in diagnostics, and potential point-of-care diagnostic opportunities for the lab.

The second episode in our series looks to address clinical management in a time when antimicrobial resistance appears to be growing.

Here is our inaugural podcast with our host, Rodney E. Rohde, PhD, SV/SM/MB(ASCP)CM, FACSc, who interviews guests on connecting lab professionals to clinicians and the intricacies of assays, the next generation of diagnostics, and the nuances of interpreting test results.

Matthew M Davis, MD, MAPP elaborates on how higher COVID-19 vaccination rates may curb the virus, alleviate childhood asthma symptoms, and protect against other common colds.

Christina Rafferty, BSc, an expert from the CDC, discusses the CLASS assay for swift and accurate detection of Anopheles stephensi, which is essential for controlling malaria spread and protecting communities from resurgence in Africa.

Jared Baeten, MD, PhD emphasizes the importance of the innovative PURPOSE 1 study in the fight against HIV, coinciding with National HIV Testing Day, today serves as a reminder of the ongoing efforts to expand testing access and develop new tools to combat HIV globally.

Jason Roberts, PhD, notes that the BLING study has been a great success for infectious diseases and critical care as a research program, providing strong evidence supporting a meaningful intervention for patients, specifically in clinical cure rates and the occurrence of infections with multiresistant organisms.

Jason Roberts, PhD, discusses insights from the BLING III trial, outlining its study design and primary outcomes. His analysis centers on the clinical benefits of continuous infusions while addressing the complexities of antibiotic administration in critical care. This is part 1 of a 2-part series.

In the last segment of the series, Jones offered his insights for when he considers discharging patients.

In this conversation, Jones discussed concerns around empirical antimicrobial treatment and opportunities to narrow down therapies.

With the recent phase 3 data results of the Moderna COVID-19-influenza combination vaccine, the company is working towards regulatory approval and opens the door to possible protection against multiple viruses with less immunizations.

Bruce Jones, PharmD, FIDSA, BCPS offered clinical considerations for patient dosing and clinical management strategies associated with concurrent therapy.

Bruce Jones, PharmD, FIDSA, BCPS provides commentary on treating challenging patients with comorbidities such as type 2 diabetes, higher BMI, and advanced age.

In the fourth and final episode, the clinicians speak of the need for greater uptake of the RSV vaccines, overcoming an "RSV identity crisis," and the potential ancillary benefit of reducing bacterial infections.

Our experts discuss the potential subgroups who might benefit from the vaccines and their safety profiles.

In part 2 of a 4-part series, clinicians discuss the efficacy, and the mechanism of action of the approved RSV vaccines, including the newly approved Moderna vaccine, mRNA 1345 (mRESVIA).

This is the first in a series of discussions between medical peers around RSV vaccines and specifically the newly approved Moderna RSV vaccine for seniors.

Minnie Hatch was in her late teens when she was diagnosed with the infection. Since then, she has had recurrent episodes and dealt with care challenges along the way.

At Digestive Disease Week, Paul Feuerstadt MD, FACG, AGAF and fellow investigators explore the potential impact of non-antibiotic medications on gut health and their association with recurrent CDI.

Insights from research on bloodstream infections with key attributions from study researcher Arden Baylink PhD.

The new Equity in Antimicrobial Stewardship Efforts (EASE) is a comprehensive set of priorities designed to overcome inequities and address the challenges with prescribing practices within the minoritized populations.

Insights from Dr. Md Zahidul Alam on treatments and prevention strategies for C difficile infection (CDI), supported by the CDC's recent study on CDI management in healthcare settings.

Photini Sinnis MD, professor at the Johns Hopkins School of Public Health and Deputy Director of the Johns Hopkins Malaria Research Institute, offers her expert insights into this zoonotic disease.

Danjuma Adda on WHO's efforts against Hepatitis B and his call for global vaccination and treatment efforts.

Dr. Thomas Holland discusses the breakthrough in antibiotic development.

In today’s world of sophisticated, complex tests, an evolving relationship between laboratory professionals and clinicians can aid in providing a quicker diagnosis and help to achieve better patient outcomes.

The company’s investigational vaccine, V116, is a conjugate vaccine and demonstrated immunogenicity for all 21 serotypes across the studied adult groups.